Lack of the chondrocyte IGF-I receptor leads to perinatal death and alterations in extracellular matrix protein expression in vitro

Autor: ⁎<%2Fce%3Asup>%2C+J%2E%22">HeiligYe L; Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich., Urbanik T; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Welte S; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; Department of Radiooncology, University Hospital Heidelberg, Heidelberg, Germany., Leblond AL; Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Zurich, Switzerland., Heilig CE; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Rahbari M; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany., Ali A; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany., Gallage S; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany., Lenoir B; Clinical Cooperation Unit 'Applied Tumor Immunity', German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Wilhelm N; Clinical Cooperation Unit 'Applied Tumor Immunity', German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany., Gärtner U; Interfaculty Biomedical Research Facility, University of Heidelberg, Heidelberg, Germany., Ogrodnik SJ; Division of Cancer Genome Research, German Cancer Research Center (DKFZ), Heidelberg, Germany., Springfeld C; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Tschaharganeh D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Helmholtz-University Group 'Cell Plasticity and Epigenetic Remodeling', German Cancer Research Center (DKFZ), Heidelberg, Germany., Fröhling S; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Translational Medical Oncology, NCT Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Longerich T; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Schulze-Bergkamen H; Department of Internal Medicine II, Marien-Hospital, Wesel, Germany., Jäger D; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Brandl L; Institute of Pathology, Medical Faculty, Ludwig-Maximilians-University, Munich, Germany., Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Straub BK; Department of General Pathology, University Hospital Mainz, Mainz, Germany., Weber A; Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Zurich, Switzerland., De Toni EN; Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich., Goeppert B; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Heikenwalder M; Division of Chronic Inflammation and Cancer, German Cancer Research Center Heidelberg (DKFZ), Heidelberg, Germany.; The M3 Research Center, University Clinic Tübingen (UKT), Medical faculty, Tübingen, Germany., Jackstadt R; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Cancer Progression and Metastasis Group, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany., Roessler S; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Breuhahn K; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany., Köhler BC; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2024 Aug 01; Vol. 80 (2), pp. 278-294. Date of Electronic Publication: 2023 Nov 02.

ZygosityPredictor.

Autor: Rheinnecker M; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Fröhlich M; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany., Rübsam M; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Paramasivam N; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Heilig CE; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Division of Translational Medical Oncology, NCT Heidelberg and DKFZ, 69120 Heidelberg, Germany., Fröhling S; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Division of Translational Medical Oncology, NCT Heidelberg and DKFZ, 69120 Heidelberg, Germany., Schlenk RF; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Department of Medical Oncology, NCT Heidelberg, Heidelberg University Hospital, 69120 Heidelberg, Germany.; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, 69120 Heidelberg, Germany.; NCT Trial Center, NCT Heidelberg, Heidelberg University Hospital and DKFZ, 69120 Heidelberg, Germany., Hutter B; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany., Hübschmann D; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Pattern Recognition and Digital Medicine Group, 69120 Heidelberg, Germany.; Innovation and Service Unit for Bioinformatics and Precision Medicine, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Publikováno v: Bioinformatics advances [Bioinform Adv] 2024 Feb 06; Vol. 4 (1), pp. vbae017. Date of Electronic Publication: 2024 Feb 06 (Print Publication: 2024).

Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions.

Autor: Schöpf J; Division of Applied Functional Genomics, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Uhrig S; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg, and DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Heilig CE; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Lee KS; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Walther T; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Carazzato A; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Dobberkau AM; Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Weichenhan D; Division of Cancer Epigenomics, DKFZ, Heidelberg, Germany., Plass C; Division of Cancer Epigenomics, DKFZ, Heidelberg, Germany., Hartmann M; Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Diwan GD; Bioquant, Heidelberg University, Heidelberg, Germany.; Heidelberg University Biochemistry Center (BZH), Heidelberg, Germany., Carrero ZI; Department for Translational Medical Oncology, NCT, NCT/UCC Dresden, a Partnership Between DKFZ, Heidelberg Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany., Ball CR; Department for Translational Medical Oncology, NCT, NCT/UCC Dresden, a Partnership Between DKFZ, Heidelberg Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD, Dresden, Germany.; Faculty of Biology, TUD Dresden University of Technology, Dresden, Germany., Hohl T; Division of Applied Functional Genomics, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Kindler T; University Cancer Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.; Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.; German Cancer Consortium (DKTK), Mainz, Germany., Rudolph-Hähnel P; University Cancer Center Mainz, Johannes Gutenberg University Mainz, Mainz, Germany.; Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany.; German Cancer Consortium (DKTK), Mainz, Germany., Helm D; Proteomics Core Facility, DKFZ, Heidelberg, Germany., Schneider M; Proteomics Core Facility, DKFZ, Heidelberg, Germany., Nilsson A; Pediatric Oncology and Coagulation, Karolinska University Hospital, Stockholm, Sweden., Øra I; Pediatric Oncology and Hematology, Skåne University Hospital, Lund University, Lund, Sweden., Imle R; Soft-Tissue Sarcoma Junior Research Group, DKFZ, Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ) and NCT Heidelberg, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany., Banito A; Soft-Tissue Sarcoma Junior Research Group, DKFZ, Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ) and NCT Heidelberg, Heidelberg, Germany., Russell RB; Bioquant, Heidelberg University, Heidelberg, Germany.; Heidelberg University Biochemistry Center (BZH), Heidelberg, Germany., Jones BC; German Cancer Consortium (DKTK), Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ) and NCT Heidelberg, Heidelberg, Germany.; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany., Lipka DB; Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany., Glimm H; Department for Translational Medical Oncology, NCT, NCT/UCC Dresden, a Partnership Between DKFZ, Heidelberg Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD, Dresden, Germany.; Translational Functional Cancer Genomics, DKFZ, Heidelberg, Germany., Hübschmann D; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg, and DKFZ, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Pattern Recognition and Digital Medicine Group, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany., Hartmann W; Gerhard Domagk Institute of Pathology, University Hospital Münster, Münster, Germany., Fröhling S; Division of Translational Medical Oncology, DKFZ, and NCT Heidelberg, Heidelberg, Germany. stefan.froehling@nct-heidelberg.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. stefan.froehling@nct-heidelberg.de.; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany. stefan.froehling@nct-heidelberg.de., Scholl C; Division of Applied Functional Genomics, German Cancer Research Center (DKFZ), and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany. claudia.scholl@nct-heidelberg.de.

Publikováno v: Nature communications [Nat Commun] 2024 Jan 02; Vol. 15 (1), pp. 51. Date of Electronic Publication: 2024 Jan 02.

BRAF ^Δβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.

Autor: Lauinger M; Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany., Christen D; Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Klar RFU; Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Freeze-O Organoid Bank, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Department of Internal Medicine I (Hematology, Oncology, and Stem Cell Transplantation), University Hospital of Freiburg, Freiburg, Germany.; Institute of Medical Bioinformatics and Systems Medicine (IBSM), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Roubaty C; Department of Biology, University of Fribourg, 1700 Fribourg, Switzerland., Heilig CE; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Stumpe M; Department of Biology, University of Fribourg, 1700 Fribourg, Switzerland., Knox JJ; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Radulovich N; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Tamblyn L; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Xie IY; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Horak P; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Forschner A; Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Eberhard Karls University, Tübingen, Germany., Bitzer M; German Cancer Consortium (DKTK), DKFZ partner site Tübingen, Eberhard Karls University, Tübingen, Germany.; Center for Personalized Medicine Tübingen, Eberhard Karls University, Tübingen, Germany.; Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany., Wittel UA; Department of General and Visceral Surgery, University of Freiburg Medical Center, Faculty of Medicine, 79106 Freiburg, Germany., Boerries M; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Institute of Medical Bioinformatics and Systems Medicine (IBSM), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Ball CR; Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Technische Universität Dresden, Faculty of Biology, Technische Universität Dresden, Dresden, Germany., Heining C; Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany., Glimm H; Department for Translational Medical Oncology, National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; German Cancer Consortium (DKTK), Dresden, Germany.; Translational Functional Cancer Genomics, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany., Fröhlich M; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Hübschmann D; German Cancer Consortium (DKTK), Heidelberg, Germany.; Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Pattern Recognition and Digital Medicine Group, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany., Gallinger S; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Fritsch R; Department of Internal Medicine I (Hematology, Oncology, and Stem Cell Transplantation), University Hospital of Freiburg, Freiburg, Germany.; Department of Medical Oncology and Haematology, University Hospital of Zurich, Zurich, Switzerland., Fröhling S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., O'Kane GM; PanCuRx Translational Research Initiative, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Dengjel J; Department of Biology, University of Fribourg, 1700 Fribourg, Switzerland., Brummer T; Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, 79104 Freiburg, Germany.; German Cancer Consortium (DKTK), partner site Freiburg and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Freeze-O Organoid Bank, University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Comprehensive Cancer Center Freiburg (CCCF), Medical Center, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.; Center for Biological Signalling Studies BIOSS, University of Freiburg, 79104 Freiburg, Germany.

Publikováno v: Science advances [Sci Adv] 2023 Sep; Vol. 9 (35), pp. eade7486. Date of Electronic Publication: 2023 Sep 01.

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

Autor: Jahn A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Rump A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Widmann TJ; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Heining C; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresden, Germany., Horak P; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Hutter B; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany., Paramasivam N; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany., Uhrig S; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany., Gieldon L; Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany., Drukewitz S; German Cancer Consortium (DKTK) Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany., Kübler A; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Bermudez M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Hackmann K; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Porrmann J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Wagner J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Arlt M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Franke M; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Fischer J; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Kowalzyk Z; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., William D; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany., Weth V; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany., Oster S; German Cancer Consortium (DKTK) Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany., Fröhlich M; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany., Hüllein J; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany., Valle González C; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany; University of Seville, Seville, Spain., Kreutzfeldt S; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Mock A; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Medical Oncology, NCT Heidelberg and Heidelberg University Hospital, Heidelberg, Germany., Heilig CE; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Lipka DB; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Möhrmann L; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresden, Germany., Hanf D; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresden, Germany., Oleś M; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany., Teleanu V; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Allgäuer M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Ruhnke L; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Kutz O; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany., Knurr A; Department of Medical Informatics for Translational Oncology, DKFZ, Heidelberg, Germany., Laßmann A; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Endris V; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Neumann O; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Penzel R; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Beck K; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Richter D; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresden, Germany., Winter U; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Wolf S; German Cancer Consortium (DKTK), Heidelberg, Germany; High-Throughput Sequencing Unit, Genomics and Proteomics Core Facility, DKFZ, Heidelberg, Germany., Pfütze K; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany., Geörg C; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany., Meißburger B; German Cancer Consortium (DKTK), Heidelberg, Germany; Sample Processing Laboratory, Molecular Diagnostics Program, NCT Heidelberg and DKFZ, Heidelberg, Germany., Buchhalter I; Omics IT and Data Management Core Facility, DKFZ, Heidelberg, Germany., Augustin M; Department of Hematology and Oncology, Klinikum Nuremberg, Paracelsus Medical University, Nuremberg, Germany., Aulitzky WE; Department of Hematology, Oncology and Palliative Medicine, Robert Bosch Hospital, Stuttgart, Germany., Hohenberger P; Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Heidelberg University, Mannheim, Germany; Division of Surgical Oncology and Thoracic Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Kroiss M; Department of Medicine I, Würzburg University Hospital, Würzburg, Germany; Comprehensive Cancer Mainfranken, University of Würzburg, Würzburg, Germany; Department of Medicine IV, University Hospital, Ludwig Maximilians University Munich, Munich, Germany., Schirmacher P; German Cancer Consortium (DKTK), Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Schlenk RF; German Cancer Consortium (DKTK), Heidelberg, Germany; Department of Medical Oncology, NCT Heidelberg and Heidelberg University Hospital, Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; NCT Trial Center, NCT Heidelberg and DKFZ, Heidelberg, Germany., Keilholz U; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; DKTK, Berlin, Germany., Klauschen F; DKTK, Berlin, Germany; Institute of Pathology, Charité - Universitätsmedizin Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany., Folprecht G; German Cancer Consortium (DKTK) Dresden, Germany; Department of Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Bauer S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; DKTK, Essen, Germany., Siveke JT; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; DKTK, Essen, Germany; Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany; Division of Solid Tumor Translational Oncology, DKTK, Essen, and DKFZ, Heidelberg, Germany., Brandts CH; University Cancer Center (UCT) Frankfurt, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; DKTK, Frankfurt, Germany., Kindler T; UCT Mainz, Johannes Gutenberg University Mainz, Mainz, Germany; Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany; DKTK, Mainz, Germany., Boerries M; Comprehensive Cancer Center Freiburg, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Institute of Medical Bioinformatics and Systems Medicine, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; DKTK, Freiburg, Germany., Illert AL; Comprehensive Cancer Center Freiburg, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; DKTK, Freiburg, Germany; Department of Internal Medicine I, University of Freiburg Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., von Bubnoff N; DKTK, Freiburg, Germany; Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Lübeck, Germany., Jost PJ; Department of Hematology and Oncology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria; DKTK, Munich, Germany., Metzeler KH; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Bitzer M; Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; DKTK, Tübingen, Germany., Schulze-Osthoff K; DKTK, Tübingen, Germany; Department of Molecular Medicine, Interfaculty Institute for Biochemistry, University of Tübingen, Tübingen, Germany., von Kalle C; Clinical Study Center, Charité - Universitätsmedizin Berlin, and Berlin Institute of Health, Berlin, Germany., Brors B; German Cancer Consortium (DKTK), Heidelberg, Germany; Division of Applied Bioinformatics, DKFZ, Heidelberg, Germany., Stenzinger A; German Cancer Consortium (DKTK), Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Weichert W; DKTK, Munich, Germany; Institute of Pathology, Technical University Munich, Munich, Germany., Hübschmann D; German Cancer Consortium (DKTK), Heidelberg, Germany; Computational Oncology Group, Molecular Precision Oncology Program, NCT Heidelberg and DKFZ, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany., Fröhling S; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany., Glimm H; German Cancer Consortium (DKTK) Dresden, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Department of Translational Medical Oncology, NCT Dresden and DKFZ, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany., Schröck E; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany; Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany. Electronic address: Evelin.Schroeck@uniklinikum-dresden.de., Klink B; Institute for Clinical Genetics, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany, ERN-GENTURIS, Hereditary Cancer Syndrome Center, Dresden, Germany; German Cancer Consortium (DKTK) Dresden, Germany; National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Personalized Oncology, National Center for Tumor Diseases (NCT) Dresden and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Core Unit for Molecular Tumor Diagnostics, NCT Dresden and DKFZ, Dresden, Germany; National Center of Genetics (NCG), Laboratoire National de Santé (LNS), Dudelange, Luxembourg; Department of Cancer Research (DoCR), Luxembourg Institute of Health (LIH), Luxembourg, Luxembourg.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Nov; Vol. 33 (11), pp. 1186-1199. Date of Electronic Publication: 2022 Aug 18.